Virtual screening is a logical first step for identifying candidate ligands for PROTAC development. In the case of PHIP, where high-affinity ligands are scarce, a structure-based virtual screening strategy can help prioritize compounds with predicted strong binding affinity and structural complementarity to the PHIP binding site. Since virtual screening results are predictive, the top-ranked candidates should then be evaluated experimentally.

In vitro binding assays such as surface plasmon resonance (SPR) or affinity selection mass spectrometry (ASMS) can confirm direct binding to PHIP. Compounds demonstrating robust affinity can then serve as PROTAC warheads, enabling selective degradation of PHIP while minimizing off-target effects on other bromodomain-containing proteins.

The answer to this question comes from MedChemExpress Technical Support.

[email protected]

To find and check out good PHIP ligands for making PROTACs, start by focusing on its bromodomain part—it's the spot that's easiest to target. There are already some starting points from earlier screens, like weak binders from fragment libraries, and crystal structures to guide you.

Here's a solid plan that works step by step:

First, for discovery: Grab fragment libraries and test them against the purified bromodomain using thermal shifts or NMR to spot hits. Then, use X-ray to see how they bind and tweak them chemically to make stronger ones, aiming for something that sticks really well, say under a micromolar. You can also run virtual screens on big compound databases, docking them into the protein structure to find new ideas with spots for attaching PROTAC linkers.

Next, tweak for PROTACs: Add flexible linkers to your ligand where it won't mess up binding—use those crystal pics to pick the right spot—and hook it up to an E3 ligase recruiter like from thalidomide or VHL. Run simulations to predict if the whole thing will form a stable complex without clashing.

For validation: Measure how tight the binding is with calorimetry or surface plasmon, and check it's picky, not hitting other similar proteins. In cells, like melanoma lines where PHIP matters, dose with your PROTAC and watch if PHIP levels drop via blots or tags—aim for effective degradation at low doses. Prove it's working right by blocking the proteasome or competing with parts, and use assays to confirm the ternary setup. If it looks good, test in animals for real-world use, optimizing for absorption.